Nano-X Imaging Ltd. · Q2 2025 earnings

Briefing

Nano-X grows revenue to $3.0M while expanding Nanox.ARC pipeline and preparing first EU shipment

NANO-X IMAGING LTD reported second quarter 2025 revenue of $3.0 million, up from $2.7 million in the prior-year quarter, driven by teleradiology services, imaging system sales and deployment, and AI solutions. The company posted a net loss of $14.7 million versus $13.6 million a year ago, with non-GAAP net loss attributable to ordinary shares of $10.9 million compared with $8.4 million. GAAP gross loss was $3.2 million on a (107%) gross loss margin, while non-GAAP gross loss was $0.6 million. Management said Nanox is on track to meet its year-end system deployment target, with revenues expected to accelerate in the second half of 2025, and highlighted FDA intent to submit the TAP2D 510(k) module, U.S. imaging center chain wins, and preparation for the first European system shipment from Romania.

• Revenue rose to $3.0 million from $2.7 million, including $2.7 million from teleradiology, $221 thousand from imaging systems/OEM, and $96 thousand from AI solutions.
• Net loss widened to $14.7 million from $13.6 million; non-GAAP net loss attributable to ordinary shares was $10.9 million versus $8.4 million.
• Non-GAAP basic and diluted loss per share was $0.17 in Q2 2025 compared with $0.14 in Q2 2024.
• Nanox notified the FDA of intent to submit the TAP2D 510(k) software module and expanded its commercial pipeline, including training at a major U.S. imaging provider.
• Management expects second-half 2025 revenue growth as Nanox.ARC deployments accelerate toward the company’s year-end deployment target.

Headline financials

Revenue & EPS history

Management said Nanox is on track to meet its year-end Nanox.ARC system deployment target and expects revenues to increase in the second half of 2025 as deployments accelerate.